Dual role of interleukin-33 in tumors.
10.11817/j.issn.1672-7347.2021.190678
- Author:
Qianqian LIU
1
,
2
;
Di LU
1
;
Jiahua HU
1
;
Junchao LIANG
3
;
Huoying CHEN
1
,
4
,
5
Author Information
1. Lingui College of Clinical Medicine, Guilin Medical University, Guilin Guangxi
2. 570236803@qq.com.
3. Department of Traditional Chinese Medical Orthopedics, Eighth People's Hospital of Foshan, Foshan Guangdong 528200, China.
4. fobufo@
5. com.
- Publication Type:Journal Article
- Keywords:
interleukin-33;
suppression of tumorigenicity 2;
tumor;
tumor microenvironment
- MeSH:
Cytokines;
Humans;
Interleukin-33/genetics*;
MAP Kinase Signaling System;
NF-kappa B/metabolism*;
Neoplasms
- From:
Journal of Central South University(Medical Sciences)
2021;46(2):169-175
- CountryChina
- Language:English
-
Abstract:
Interleukin-33 (IL-33) is a new member of the IL-1 cytokine family which plays roles in the nucleus as a nuclear factor and is released by damaged or necrotic cells to act as a cytokine. It can be released via damaged or necrotic cells and functions as a cytokine. The released IL-33 activates the downstream NF-κB and MAPKs signaling pathways through the isomers of the specific receptor ST2 and the interleukin-1 receptor accessory protein (IL-1RAcP), resulting in danger signals and the activated multiple immune responses. IL-33 is abnormally expressed in various tumors and involves in tumorigenesis, development, and metastasis. Moreover, IL-33 can play both pro-tumor and anti-tumor roles in the same type of tumor.
